MONTPELLIER, France, July 20, 2016 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots announced revenue results for its fiscal fourth quarter and full year ended June 30, 2016. For fiscal year 2016, the Company reported a 73% increase in revenue to €11.2 million.
|In thousands of Euros||2014/2015||2015/2016|
(April 1 to June 30)
|3 109||4 199|
|Annual revenue |
(July 1 to June 30)
|6 517||11 264|
Acceleration in growth of the ROSA® installed base worldwide. Up 71% over the past year.
At the end of fiscal year 2016, Medtech announced a significant increase in its total installed base of ROSA® robots worldwide. The fleet has now increased to 82 ROSA® robots, compared with 48 in the previous year. The current geographic distribution of the installed base is as follows: 22 robots in Europe, 43 in North America and 17 in the rest of the world.
During fiscal year 2016, Medtech sold 34 ROSA® robots worldwide, including 22 in the United States. In comparison, Medtech sold 20 ROSA® robots worldwide, including 13 in the United States, in the previous fiscal year.
In its fiscal fourth quarter (from April 1 to June 30, 2016), Medtech sold 13 robots worldwide compared with 10 robots sold during the fiscal fourth quarter of 2015.
As of June 30, 2016, Medtech had €17.9 million in cash available compared with €20.2 million at the end of March 2016 and €12 million at the end of June 2015.
Bertin Nahum, CEO and Founder of Medtech, commented: “We are very proud of the significant growth achieved during fiscal 2016, as our commercial team delivered on our market expansion strategy for the year. This excellent performance highlights our ability to successfully grow our business on an international scale.”
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA®, an innovative technological device devoted to brain surgery procedures. ROSA® has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 email@example.com PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 firstname.lastname@example.org Joanna Zimmerman (US) Tel : +1 646-536-7006 email@example.com